admnaturis

/admnaturis
­

About admnaturis

This author has not yet filled in any details.
So far admnaturis has created 24 blog entries.

Víctor Infante talks about: ASEBIO Report 2016

 

QUESTION: In terms of KPIs, the report points out that companies in which biotechnology is its core activity has led the growth ranking during 2015. Has Bionaturis been involved in this growth? If so, in what way?

 

ANSWER: Bionaturis group is showing a growing trend at both organic and inorganic levels. For example, in the period 2012-15 our recurring net sales grew at 24.1% CAGR and in the year ended 2016 we have grown again 24.9% YoY. In terms of inorganic growth, we fully acquired Biobide in 2014- the world leader CRO in the use of zebrafish as an animal- and ZIP Solutions -former Era Biotech- in 2016 being triggered by the signing of an exclusive worldwide license agreement of ZIP´s Splittera system to a multinational sector. Thus, our high value portfolio of premium assets is growing at a steady pace and now our strategic purpose is to optimize as much as possible their ROI in the coming years.

 

QUESTION: The report says that the biotechnology sector has not been able yet to recover itself for the sharp drop back in 2013. However, in 2015 the economic impact of the biotech companies has reached 8.6% of Spanish GDP coming from a 10.35% figure for 2014. Shall we expect to see a positive uptrend or is it dependent on perspective?

 

ANSWER: As always, the data have to be analyzed from many angles and perspectives. The overall figure is positive because it could be that we are seeing a new upward trend that will have to be confirmed in the following years. For me it is more important not only to compare it in isolation on the overall impact on Spanish GDP but how we are at a relative level […]

August 8th, 2017|Blog english|0 Comments

Bionaturis signs a convertible loan with BTC diez investment fund

For the official disclosing Click here (only in Spanish)

https://www.bolsasymercados.es/mab/documentos/HechosRelev/2017/08/84980_HRelev_20170802.pdf

August 2nd, 2017|Blog english, last news|0 Comments

Biobide hits September with three international events

Eurotox 2016, the European Teratology Society (ETS) Meeting and the IV International Congress of Research and Innovation of Neurodegenerative Diseases are the three international events for Biobide -Bionaturis Group- to hit September. The first one, organized by the European Societies of Toxicology, will be held in Seville on 4-7th, September, with the theme “Protecting Public and Environmental Health by Understanding and Communicating Toxicology”.

The organization of this international event, which has received more than 900 abstracts to be presented as posters, has planned six Continuing Education Courses, 16 Symposia, 10 Workshops as well as Keynote Lectures from key scientists. More than 50 companies have provided their supports as exhibitors. Biobide will be one of them with the booth number 18, assisted by Arantza Muriana, the R&D Management Director of Biobide.

“The presence of Biobide in international forums is essential to be informed and updated about the news and needs of our sector as well as in the business field strictly. On the other hand, these events confirm us the increasing interest of companies and institutions in the use of zebrafish as an alternative animal model, which makes us improve our services constantly and, then, our competitiveness”, Arantza Muriana has stated.

ETS Meeting, in Dublin

The second meeting in Biobide’s schedule in September will be in Dublin (Ireland) for the 44 edition of the European Teratology Society (ETS) Meeting, held on 11-14th. This event will celebrate lectures and forums about relevant topics such as maternal health in pregnancy or the regulatory updates about developmental and reproductive toxicology.

During this high-level event, Biobide will present three scientific posters titled “An inter-laboratory validation of the zebrafish embryo assay for the detection of developmental toxicity”, “Standarized Light/Dark preference test for anxiety and stress research using […]

August 30th, 2016|Blog english, congress|Comments Off on Biobide hits September with three international events

August Newsletter

Let’s read Bionaturis Group latest news

IN THIS ISSUE

Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biotechnology private investment increases

Let’s get to know…

Lucia Beltran Camacho, 22 years old, born in Tarifa (Cadiz). Degree at Biotechnology by Cadiz University.

 

 

 

-When you were a child, what did you want to be as an adult?
I have always loved everything related to music so I wanted to be a music teacher.
-What do you like the most about your job?
Learning and finding out new things every day.
-What are your future challenges?
Carrying on learning and progressing in order to work as a researcher.
-Your favourite dish
Lasagne.
-A place
Any beach.
-A film
‘Amelie’ ,by Jean-Pierre Jeunet.
-A historical figure
Rosalind Franklin.
-A book
‘The Silver Linings Playbook’, by Matthew Quick.
-A song
‘La piedra invisible’, by Izal.
-What do you usually do in your free time?
I like going to the cinema and spending time with my family and friends. If I have enough time, I love travelling and knowing new places.
-You can’t live without…
Chocolate.
-How do you imagine the world in 20 years?
A world where Science is more important than now and people bet on the progresses that it can offer.

Lucia has been doing a Lab Technician internship at Bionaturis since July, 2016.

Biobide takes part in a research about Malaria funded by Melinda
and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the latest two years. The final end is public institutions and […]

August 9th, 2016|Blog english|Comments Off on August Newsletter

About the non-monetary capital increase

Relevant information about the non-monetary capital increase that lets Inveready Innvierte Biotech II access to Bionaturis shareholders

 

For the official disclosing, please, click here

August 8th, 2016|Hechos Relevantes|Comments Off on About the non-monetary capital increase

Biotechnology private investment increases

The biotech sector continues gaining relevance in the Spanish economy, according to the 2015 Asebio Report, recently published. Among the criteria that show this increasing trend, it is worth noting the private R&D investment, that has returned to growth with 3,75% (533.8 million Euros in 2014) after two consecutive years of downturn. This tendency contrasts to the needs of this sector, that requires an increase of the public economic aids for R&D in order to recuperate, at least, the previous levels to 2008.

“The figures of the report confirm that the biotech sector is a cornerstone in the Spanish economy. The growth in the R&D private investment points out that the companies have made a great effort to continue developing and innovating despite the numerous problems. These figures are endorsed internationally by the latest Ernst&Young Report – Beyond Borders- that shows how the global biotech sector reached a record figure of funding until 62,000 million Euros in 2015”, Bionaturis CEO, Victor Infante, has stated.

The invoicing volume is also very relevant considering that it has already reached 10.35% of the Spanish GDP, rubbing shoulders for the first time in the top ranking with other sectors such as Tourism. This indicator has not stopped growing up even during the crisis, period in which, precisely, it has registered a rise of more than 7%. In 2014 the sector overtook the record of 100,000 million Euros of invoicing and created 178,000 jobs (+3%).

The number of biotech companies (high-technology companies completely devoted to the sector, as Bionaturis Group) grew 13.36% in 2014. As in previous reports, the majority of these companies consider that the internationalization is very important for their growth, because of that, the 86% of the companies integrated in […]

August 8th, 2016|Blog english|Comments Off on Biotechnology private investment increases

Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the lastest two years. The final end is public institutions and the industry sharing more open knowledge in order to progress in new joint developments.

The promising results have just been published in a scientific paper and include the toxicity assays in zebrafish performed by Biobide to test the potential toxicity of the candidates to fight malaria. “Our presence in this study shows the versatility and usefulness of the zebrafish as animal model for drug discovery, as well as our expertise in this field. In addition to the obvious scientific value, this collaborative project has also a very relevant social value for Biobide, that is contributing in this way to find solutions for a disease that affected 95 countries worldwide in 2015”, the R&D Management Director at Biobide, Arantza Muriana, has stated.

In the 290 assays made by the different researchers for this study, 130 compounds have shown potential action against malaria which paves the way for a future election of the most suitable ones to develop new drugs. Additionally, some of these compounds have also shown outstanding activity against other disease agents, including bacteria, fungi, other parasites and even human cancer cells. In fact, these positive results have ignited over 30 drug development program devoted to fight different diseases. This initiative has been so satisfying that promoters are already repeating the […]

August 2nd, 2016|Blog english|Comments Off on Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Change in the liquidity provider

For the official disclosing, please, click here (only in Spanish)

August 1st, 2016|Hechos Relevantes|Comments Off on Change in the liquidity provider

July Newsletter

If you want to know Bionaturis Group latest news, here you are our July Newsletter

IN THIS ISSUE

Miriam Bastida, ZIP Solutions: “We want to grow and gain international position with Bionaturis Group”

 

Bionaturis debates about the potentiality of the Biotech sector in Andalusia

Let’s get to know…

Nuria Martinez Mas, born in Manresa, PhD at Organic Chemistry and Biochemistry by Ramon Llull University in Barcelona.

 

-When you were a child, what did you want to be as an adult?
A doctor, but seeing blood, although it is not mine, makes me feel very nervous. Because of that I had to change my calling!
-What do you like the most about your job?
It lets me learn something new every day.
-What are your future challenges?
I would like to know more about patents. It is a very complex field and it is not my proposal becoming an expert but I think that in my current position I need more knowledge because it can influence in the commercial strategy of the company and therefore in the projects we are working on.
-Your favourite dish
I prefer simple dishes. I enjoy a lot with bread, tomato and a good iberian ham.
-A place
The National Park of Aigüestortes, in the Pyrenees.
-A film
‘Life is beautiful’, by Roberto Benigni.
-A historical figure
Marie Curie, a guide for all the women who work in science.
-A book
Anything by Jo Nesbo, a Norwegian writer of crime novels.
-A song
‘Al mar’, by Manel, a catalan band.
-What do you usually do in your free time?
Free time? What is that? With a one-year-old baby, I do not have much! But when it is possible, I like going with my partner to climb 3,000 metre mountains.
-You can’t live without…
The light of the sun, it is vital to have energy and good mood.
-How do […]

July 13th, 2016|Blog english|Comments Off on July Newsletter

Miriam Bastida, ZIP Solutions: “We want to grow and gain international position with Bionaturis Group”

Bionaturis Group continues increasing its high-quality products and services offer for human and animal health in its national and international expansion signing collaboration agreements with third relevant parties, creating new subsidiaries in strategic markets and integrating new companies in its structure by M&A transactions. The latest acquisition of Bionaturis Group is Zera Intein Protein Solutions, ZIP Solutions, an international cutting-edge company well known by its industrial solutions for the expression and purification of biological products, one of the highest growing fields in the Health sector. ZIP’s General Manager, Miriam Bastida, stands out the potentialities of the company and its goals in this new stage.

-What is the speciality of ZIP Solutions?

ZIP Solutions is a biotechnological company devoted to develop and commercialise innovative solutions for industrial and pharmaceutical applications. The company has an in-depth knowledge of the requirements of the human and animal health industry, and offers its proprietary solutions, Zera® and Splittera, as differentiating and highly competitive tools to meet their demanding needs. These solutions, having a wide range of applications, are able to produce, for example, biological products that could turn into first in class vaccines and industrial enzymes (in the case of Zera®), also being part of effective cancer treatments as conjugated antibodies (ADCS) or the standardization of diagnosis kits (Splittera). Besides, Splittera offers a solution for an underserved need within the lucrative sector of biodrugs such as its industrial downstream purification. It is worth noting that nowadays biodrugs, with a global market of $165 billion and a double-digit growth rate, are the top runners of the rankings leading, for instance the top sales worldwide –Humira, by Abbvie, with $14 billion annual sales- or the top-five list on oncological products. Its growth continues unstoppable […]

July 12th, 2016|Blog english|Comments Off on Miriam Bastida, ZIP Solutions: “We want to grow and gain international position with Bionaturis Group”

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR